Related Experiment Video
Updated: Apr 11, 2026

Fully Processed Recombinant KRAS4b: Isolating and Characterizing the Farnesylated and Methylated Protein
Published on: January 16, 2020
GTP-Dependent K-Ras Dimerization
Serena Muratcioglu1, Tanmay S Chavan2, Benjamin C Freed3
1Department of Chemical and Biological Engineering, Koc University, Rumelifeneri Yolu, 34450 Sariyer Istanbul, Turkey.
Abstract:
Ras proteins recruit and activate effectors, including Raf, that transmit receptor-initiated signals. Monomeric Ras can bind Raf; however, activation of Raf requires its dimerization. It has been suspected that dimeric Ras may promote dimerization and activation of Raf. Here, we show that the GTP-bound catalytic domain of K-Ras4B, a highly oncogenic splice variant of the K-Ras isoform, forms stable homodimers. We observe two major dimer interfaces. The first, highly populated β-sheet dimer interface is at the Switch I and effector binding regions, overlapping the binding surfaces of Raf, PI3K, RalGDS, and additional effectors. This interface has to be inhibitory to such effectors. The second, helical interface also overlaps the binding sites of some effectors. This interface may promote activation of Raf. Our data reveal how Ras self-association can regulate effector binding and activity, and suggest that disruption of the helical dimer interface by drugs may abate Raf signaling in cancer.
Insights
Ras proteins, crucial for cell signaling, can form dimers. These Ras dimers influence the activity of downstream proteins like Raf, potentially offering new therapeutic targets for cancer treatment.
Area of Science:
- Molecular Biology
- Cell Signaling
- Oncology
Background:
- Ras proteins are key regulators of receptor-initiated signal transduction pathways.
- Activation of Raf, a critical downstream effector, necessitates its dimerization.
- The role of Ras dimerization in promoting Raf activation has been hypothesized.
Purpose of the Study:
- To investigate the self-association properties of the K-Ras4B catalytic domain.
- To elucidate the structural basis of Ras dimerization and its impact on effector interactions.
- To explore the therapeutic potential of targeting Ras dimerization in cancer.
Main Methods:
- Biochemical and biophysical characterization of GTP-bound K-Ras4B catalytic domain.
- Identification and analysis of Ras homodimer interfaces.
- Structural analysis of Ras-effector binding regions.
Main Results:
- The GTP-bound catalytic domain of K-Ras4B forms stable homodimers.
- Two distinct dimer interfaces were identified: a β-sheet interface and a helical interface.
- The β-sheet interface overlaps with binding sites for multiple effectors (Raf, PI3K, RalGDS) and may be inhibitory.
- The helical interface also overlaps effector binding sites and may promote Raf activation.
Conclusions:
- Ras self-association directly regulates effector binding and activity.
- Ras dimers can modulate Raf signaling through distinct interfaces.
- Targeting the helical Ras dimer interface could be a viable strategy to inhibit Raf signaling in cancer.
More Related Videos
Related Concept Videos
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
The Ras Gene
Ras is a...
MAPK Signaling Cascades
GTPases and their Regulation
Large G-proteins,...
GTPases and their Regulation
Receptor Tyrosine Kinases

